Role of PSMA-PET/MRI for diagnosis and follow-up of focal therapy of prostate cancer

Role of PSMA-PET/MRI for diagnosis and follow-up of focal therapy of prostate cancer - PSMA-FOXPRO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022363

Enrollment

Registered

2020-07-13

Start date

2020-06-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Group 1: Patients with a localised prostate cancer eligible for HIFU (high-intensity focused ultrasound) treatment: before therapy Group 2: Patients with a localised prostate cancer treated

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Biopsy proven prostate cancer - Serum PSA-level < 10ng/ml - Gleason Score = 3 + 4

Exclusion criteria

Exclusion criteria: - mpMRI or PET contraindications - contrast agent allergy - Pacemaker, neurostimulator, insulin pump - shards of metal - dental implants - other implants

Design outcomes

Primary

Measure	Time frame
Detection rate of prostate cancer Detection rate of nodal and distant metastasis Detection rate of residual / recurrent cancers after treatment	—

Secondary

Measure	Time frame
Detection rate of clinically significant prostate cancers Comparison of imaging results between multiparametric MRI, PSMA-PET and the combination of both Comparison of imaging and histopathological results with results of conventional imaging	—

Countries

Germany

Contacts

Public ContactNiklas Westhoff

Universitätsmedizin Mannheim, Klinik für Urologie und Urochirurgie

niklas.westhoff@medma.uni-heidelberg.de0621 383 2215

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026